HOSPITAL pharmacists are calling for a consistent and streamlined approach to the prescribing and dispesning of new oral COVID-19 medicines.
In an editorial published in the Journal of Pharmacy Practice and Research, senior Australian hospital pharmacists noted while there was strong clinical evidence supporting the use of the recently approved medications, they warned that "potential drug interactions can be very challenging to interpret, predict and manage".
"A recent review of COVID-19 positive patients for infusion of sotrovimab, a COVID-19 treatment provisionally approved in 2021, found up to one-in-three patients would be potentially at risk of a significant drug interaction if they commenced Paxlovid (nirmatrelvir and ritonavir) therapy," they said.
CLICK HERE to read the editorial in full.
The above article was sent to subscribers in Pharmacy Daily's issue from 11 Feb 22
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 11 Feb 22
